ZVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zevra Therapeutics Inc (ZVRA) is not a strong buy for a beginner, long-term investor at this time. While the company has shown significant revenue growth, its financial performance is weak with declining net income and EPS. The technical indicators suggest a bearish trend, and insider selling activity raises concerns. The options data indicates a neutral to slightly bullish sentiment, but the lack of recent news or strong trading signals makes it less compelling for immediate investment.
The MACD is negative and contracting, RSI is neutral at 47.654, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 8.86, with key support at 8.336 and resistance at 9.383. Overall, the technical indicators suggest a bearish trend.
The company signed an exclusive expanded access distribution agreement with Uniphar, potentially expanding the market for its drug Miplyffa. Analysts believe this opportunity is not yet priced into the stock.
Insider selling has increased significantly (809.12% over the last month), which may indicate a lack of confidence from insiders. The company's financial performance shows a sharp decline in net income, EPS, and gross margin.
In Q3 2025, revenue increased by 605.36% YoY to $26,063,000. However, net income dropped by 98.36% YoY to -$544,000, EPS fell by 98.55% YoY to -0.01, and gross margin declined significantly by 2371.50% YoY to 94.04.
H.C. Wainwright reiterated a Buy rating with a $26 price target, citing the expanded access program for Miplyffa. Analysts believe the potential of this program is not reflected in the current stock price.
